Please assess the completion status of the following clinical trial:

Trial Title: Levetiracetam or Pregabalin in Treating Seizures in Patients Undergoing Chemotherapy and/or Radiation Therapy For Primary Brain Tumors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of primary brain tumor~  * WHO grade II-IV disease~* Undergoing chemotherapy and/or radiotherapy~* No brain tumor without the potential need for chemotherapy (e.g., meningioma without anaplastic features)~* Has had at least one seizure provoked by the brain tumor, justifying introduction of antiepileptic drug (AED) treatment~  * No status epilepticus~PATIENT CHARACTERISTICS:~* Modified Rankin score \< 4 at study enrollment~* Life expectancy ≥ 4 weeks~* Not pregnant~* Negative pregnancy test~* Fertile patients must use effective contraception~* No known intolerance to the study drugs~* No pre-existing psychosis and/or current suicidality~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* No concurrent IV AEDs other than benzodiazepines~* Other concurrent AEDs, except phenobarbital, allowed provided they are discontinued within 2 weeks after study enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Levetiracetam (Type: ACTIVE_COMPARATOR): Patients assigned to Levetiracetam are treated with the initial dose of 2 x 250mg per day up to one year
- Pregabalin (Type: ACTIVE_COMPARATOR): Patients assigned to Pregabalin are treated with the initial dose of 2 x 75mg per day up to one year

Based on this trial design, predict the completion outcome and termination type (if applicable).